IKT advances IKT-001 to global pivotal Phase 3 in PAH; ATM prospectus terminated

Inhibikase Therapeutics, Inc.

IMPROVE-PAH Phase 3 trial for IKT-001 in pulmonary arterial hypertension expected to start Q1 2026 across up to 180 sites.
Adaptive two-part design: Part A (140 pts, primary endpoint PVR at Week 24) and Part B (346 pts, primary endpoint 6MWD at Week 24).
Prior Phase 2b plan replaced after FDA Type C meeting; company cites advantages of uninterrupted enrollment and dose titration.
ATM prospectus terminated with no sales made; Sales Agreement with Jefferies remains in effect without further sales pending new filings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.